{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:57:48Z","timestamp":1773669468742,"version":"3.50.1"},"reference-count":22,"publisher":"American Society of Consultant Pharmacists","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2011,1,1]]},"DOI":"10.4140\/tcp.n.2011.48","type":"journal-article","created":{"date-parts":[[2011,1,12]],"date-time":"2011-01-12T02:15:37Z","timestamp":1294798537000},"page":"48-51","source":"Crossref","is-referenced-by-count":18,"title":["Selegiline and Rasagiline: Twins or Distant Cousins? Guidelines"],"prefix":"10.4140","volume":"26","author":[{"given":"Dawn S.","family":"Knudsen Gerber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2011,1,11]]},"reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"DiPiro JT, Talbert RL, Yee GC et al. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York, NY: McGraw-Hill Medical; 2008:chap. 61.","DOI":"10.1345\/aph.1L477"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 2002;59:1937-43.","DOI":"10.1001\/archneur.59.12.1937"},{"key":"3","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trial.","volume":"365","author":"O Rascol","year":"2005","journal-title":"Lancet"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. DATATOP: a multi-center controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052-60.","DOI":"10.1001\/archneur.1989.00520460028009"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-8.","DOI":"10.1001\/archneur.62.2.241"},{"key":"6","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/mds.22218","article-title":"A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.","volume":"23","author":"CW Olanow","year":"2008","journal-title":"Mov Disord"},{"key":"7","unstructured":"U.S. Food and Drug Administration. Approved Drug Products\u2014 Eldepryl. Available at <a target=\"_blank\" href='http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails'>http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails<\/a>"},{"key":"8","unstructured":"U.S. Food and Drug Administration. Approved Drug Products\u2014 Azilect. Available at <a target=\"_blank\" href='http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails'>http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails<\/a>"},{"key":"9","unstructured":"Young D. Drug innovation on the decline. February 1, 2007. Available at <a target=\"_blank\" href='http:\/\/www.ashp.org\/import\/news\/HealthSystemPharmacyNews\/newsarticle.aspx?id=2416'>http:\/\/www.ashp.org\/import\/news\/HealthSystemPharmacyNews\/newsarticle.aspx?id=2416<\/a>"},{"key":"10","unstructured":"U.S. Food and Drug Administration. Approved Drug Products\u2014 Sinemet. Available at <a target=\"_blank\" href='http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails'>http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails<\/a>"},{"key":"11","unstructured":"U.S. Food and Drug Administration. Approved Drug Products\u2014 Requip. Available at <a target=\"_blank\" href='http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails'>http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.DrugDetails<\/a>"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Chen JJ, Lew MF, Siderowf A. Treatment strategies and qualityof-care indicators for patients with Parkinson's disease. J Manag Care Pharm 2009;15 3 Suppl:1-21.","DOI":"10.18553\/jmcp.2009.15.s3.1"},{"key":"13","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1056\/NEJMct0800326","article-title":"Levodopa for the treatment of Parkinson's disease.","volume":"359","author":"PA. Lewitt","year":"2008","journal-title":"N Engl J Med"},{"key":"14","unstructured":"Eldepryl prescribing information. 1997. Available at <a target=\"_blank\" href='http:\/\/www.l-deprenyl.com\/prescribe\/index.html'>http:\/\/www.l-deprenyl.com\/prescribe\/index.html<\/a>"},{"key":"15","unstructured":"Helms RA, Quan DJ, Herfindal ET et al. Textbook of Therapeutics: Drug and Disease Management. 8th ed. New York, NY: Lippincott Williams & Wilkins; 2006:1655,1657."},{"key":"16","unstructured":"Parkinson Study Group. Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson's disease (the TEMPO study). Neurology 2001;56 Suppl 3:345. Abstract."},{"key":"17","unstructured":"Marcaida JA. Rasagiline does not promote tyramine pressor responses. Mov Disord 2005;20 Suppl 10:133. Abstract."},{"key":"18","unstructured":"Azilect EMEA (European) prescribing information. 2005."},{"key":"19","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2146\/ajhp050395","article-title":"Rasagiline: a second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.","volume":"63","author":"JJ Chen","year":"2006","journal-title":"Am J Health Syst Pharm"},{"key":"20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/01.wnf.0000240956.49315.be","article-title":"Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.","volume":"30","author":"HH Fernandez","year":"2007","journal-title":"Clin Neuropharmacol"},{"key":"21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neulet.2003.10.067","article-title":"Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline.","volume":"355","author":"O Bar Am","year":"2004","journal-title":"Neurosci Lett"},{"key":"22","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1212\/WNL.0b013e3181a0feba","article-title":"MAO-B inhibitor know-how: back to the pharm.","volume":"72","author":"PA. Lewitt","year":"2009","journal-title":"Neurology"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T05:38:55Z","timestamp":1637127535000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2011\/00000026\/00000001\/art00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1,1]]}},"alternative-id":["L1501H252144064M"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2011.48","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1,1]]}}}